Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?

Simply Wall St.06-03 17:20

Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640134908?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-03 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640134908","market":"us","top_or_hot":-1,"title":"Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?","media":"Simply Wall St.","content":"<div>\n<p>Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-03 17:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHVN","symbol_name":"Biohaven Pharmaceutical Holding Co Ltd.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering","article_id":"2640134908","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-pkm2-and-autoimmune-pipeline-progress-altering","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640134908","pubTimestamp":1780478456,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune candidate BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy.\nThese updates showcase Biohaven’s push into metabolically targeted neurology and precision immunology, positioning its platforms around disease-causing antibodies and energy metabolism rather than symptom control alone.\nNext,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","PRGS":"Progress Software Corporation","BK4097":"系统软件","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Biohaven的PKM2和自身免疫管道进展是否会改变Biohaven(BHVN)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1.5,"PRGS":1.5},"content_text":"Biohaven recently reported a series of pipeline advances, including first-in-human dosing of BHV-8100, its oral, brain-penetrant PKM2 modulator, alongside encouraging clinical data for autoimmune candidate BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy. These updates showcase Biohaven’s push into metabolically targeted neurology and precision immunology, positioning its platforms around disease-causing antibodies and energy metabolism rather than symptom control alone. Next, we’ll examine how Biohaven’s progress with its first-in-human BHV-8100 program could influence the company’s broader investment narrative. Outshine the giants: these 14 early-stage AI stocks could fund your retirement.AdvertisementWhat Is Biohaven's Investment Narrative?For Biohaven, the investment story is really about whether its broad, high-risk pipeline can justify ongoing heavy losses and dilution. With no revenue and a net loss of about US$739.0 million in 2025, the company is leaning hard on its ability to turn pipeline science into future commercial products. The latest BHV-8100 first-in-human data, alongside BHV-1300 and BHV-1400 advances, reinforces that Biohaven is not a single-asset bet, but it does not change the near-term reality that key value inflection points still sit in pivotal trials like opakalim in focal epilepsy and BHV-1300 in Graves’ disease. In the short term, the BHV-8100 update strengthens the long-range story more than it shifts the immediate catalysts, while financing risk and a limited cash runway remain front and center. However, the combination of high cash burn and further dilution risk is something investors should understand.\n\nThe valuation report we've compiled suggests that Biohaven's current price could be inflated.Exploring Other PerspectivesBHVN 1-Year Stock Price Chart Four fair value estimates from the Simply Wall St Community span roughly US$4.30 to US$43.02 per share, underscoring how differently people weigh Biohaven’s pipeline promise against its very large losses and short cash runway.Explore 4 other fair value estimates on Biohaven - why the stock might be worth less than half the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Biohaven research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.Our free Biohaven research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biohaven's overall financial health at a glance.Curious About Other Options?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Find 46 companies with promising cash flow potential yet trading below their fair value.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biohaven might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640134908","isCrawlerRequest":true}